Shengxiang Biotech (688289.SH) products obtained medical device registration certificate

Zhitong Finance App News, Shengxiang Biology (688289.SH) announced that the company's product parainfluenza virus type 1, 2, and 3 nucleic acid detection kit (fluorescence PCR method) recently received the “Medical Device Registration Certificate” issued by the State Drug Administration.

According to reports, parainfluenza virus (PIV) is an important pathogen causing respiratory infections in infants, immunosuppressed patients, the elderly, and patients with chronic diseases. It can cause various respiratory diseases, including the common cold, otitis media, croup, bronchiolitis, and pneumonia. The parainfluenza virus can be divided into 4 different serotypes according to serotype and genomic characteristics. Among them, parainfluenza virus types 1, 2, and 3 are mainly important pathogens that cause upper respiratory infections, pneumonia, and bronchial pneumonia in patients (especially infants and young children). Since the symptoms and prevalence of these viruses are similar, it is unreliable to distinguish the pathogen based on clinical symptoms alone. Due to their simplicity and efficiency, nucleic acid detection methods are now widely used in PIV prevalence monitoring, clinical diagnosis, efficacy evaluation and prognostic judgment. In recent years, with the further development of molecular diagnostic technology, new technologies such as nucleic acid amplification and gene sequencing have gradually been applied clinically, greatly improving the detection rate of PIV.